-
Sector Analysis
Myelofibrosis Epidemiology Analysis and Forecast, 2021-2031
In the 8MM, there were 69,236 diagnosed prevalent cases of Myelofibrosis (MF) in 2021. MF belongs to a group of diseases called myeloproliferative disorders. MF is a serious bone marrow disorder that disrupts the body’s normal production of blood cells (MedlinePlus, 2020; Mayo Clinic, 2021). MF includes primary MF (PMF), which is idiopathic. At times, essential thrombocytosis (ET) or polycythemia vera (PV) could progress to MF, resulting in post-essential thrombocytosis MF (PET MF) and post-polycythemia vera MF (PPV MF), which...
-
Sector Analysis
Non-Small Cell Lung Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Non-Small Cell Lung Cancer (NSCLC) is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants. Although NSCLCs are associated with cigarette smoke, adenocarcinomas may be found in patients who have never smoked. The non-small cell lung cancer marketed and pipeline drugs market...
-
Sector Analysis
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Market Report Overview B-cell NHL generally arises in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to involve distant sites such as the lung or brain in the later stages of the disease. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence outcomes and treatment decisions. The B-Cell NHL marketed, and pipeline drugs market research report includes an assessment of...
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC (malignancy) originates in the tissues of the lungs or the cells lining the airways. Symptoms usually occur in the later stages of the disease, and include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight...
-
Sector Analysis
Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Acute Myeloid Leukemia Market Report Overview The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Moreover, the high transplant relapse rate and steady increase in incidence provide a steady flow of cell therapy-eligible patients and will drive market growth during the forecast period. Buy Full Report to Know More About the Acute Myeloid Leukemia Market Forecast Download a Free Report Sample The acute myeloid leukemia market research report offers a comprehensive insight into the market...
-
Sector Analysis
Colorectal Cancer Cell and Gene Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Colorectal Cancer Cell and Gene Therapy Market Report Overview The CRC cell and gene therapy market size across the 15MM was $18.9 billion in 2021. The market growth will be attributed to the combination therapy of OVs + ICIs in dMMR/MSI-H patients in 2L and 3L settings. Colorectal Cancer Cell and Gene Therapy Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Colorectal Cancer Cell and Gene Therapy Market Forecast Download A Free Report Sample...
-
Sector Analysis
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
B-Cell Non-Hodgkins Lymphoma Cell Therapy  Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional NHL therapies was $16.1 billion in 2021. The market growth will be attributed to the Kymriah, Yescarta, Breyanzi, and Carteyva, which will receive label expansions into earlier lines of therapy and new NHL subtypes. B-Cell Non-Hodgkins Lymphoma Cell Therapy  Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the B-Cell Non-Hodgkins Lymphoma Cell Therapy...
-
Sector Analysis
Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Report Overview Bile Duct Cancer (Cholangiocarcinoma) is a rare disease in which malignant cells form in the bile ducts that carry the digestive fluid, bile. BDC occurs mostly in people older than age 50, although it can occur at any age. The Bile Duct Cancer Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in...
-
Sector Analysis
Multiple Myeloma - Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Multiple Myeloma Cell Therapy Market Report Overview The total market value for the 15M, which includes both cell therapies and established/traditional MM therapies was $25.7 billion in 2021. The following are some of the key highlights of the multiple myeloma cell therapy market: The market growth will be attributed to the established CAR-T agents such as Abecma and Carvykt. The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.